Goldman Sachs expects Nvidia ’beat and raise,’ lifts price target to $240
Natera (NASDAQ:NTRA) CEO Steven Leonard Chapman sold 1,603 shares of common stock on October 21 at a price of $187.95, totaling $301,283. The transaction comes as the stock trades near its 52-week high, having delivered an impressive 53% return over the past year. According to InvestingPro analysis, Natera’s shares appear overvalued at current levels.
According to a Form 4 filing with the Securities and Exchange Commission, the transaction was to cover tax obligations related to the vesting of restricted stock units. On October 20, Chapman also exercised options to acquire 3,386 shares of Natera common stock. With a market capitalization of $25.94 billion and an overall Financial Health score rated as GREAT by InvestingPro, the company maintains strong fundamentals despite the insider sale.
Following the sale, Chapman directly owns 155,855 shares of Natera. Investors tracking insider movements can access comprehensive analysis and 12 additional ProTips about Natera through InvestingPro’s detailed research reports, with the next earnings announcement scheduled for November 5, 2025.
In other recent news, Natera has been active in various research and development initiatives. The company has enrolled over 1,600 patients in its EXPAND trial, which is evaluating its Fetal Focus single gene noninvasive prenatal test. This study aims to confirm test results through prenatal or postnatal diagnostic testing, involving a diverse population from multiple medical centers. Additionally, Natera’s Signatera test has shown promising results in two separate studies. The test outperformed standard tumor markers in predicting outcomes for testicular cancer patients and demonstrated strong performance in monitoring uterine cancer recurrence. In terms of analyst updates, Canaccord Genuity maintained a Buy rating with a $200 price target for Natera, highlighting its leadership in molecular residual disease testing. Meanwhile, Wells Fargo resumed coverage with an Equal Weight rating and a $175 price target, emphasizing Natera’s strong position in the cell-free DNA testing market. These developments indicate Natera’s ongoing efforts to advance its testing technologies and its recognition by analysts.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.